US Patent Issued to BIOGEN MA on April 21 for "Methods of treating inflammatory and autoimmune diseases with natalizumab" (California Inventor)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,607,638, issued on April 21, was assigned to BIOGEN MA INC. (Cambridge, Mass.).

"Methods of treating inflammatory and autoimmune diseases with natalizumab" was invented by Theodore A. Yednock (Forest Knolls, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 lev...